Pfizer in Schizophrenia Deal With Taisho (Japan)
This article was originally published in PharmAsia News
Japanese drug company Taisho Pharmaceutical has entered negotiations to outlicense an experimental schizophrenia drug to the world's biggest pharmaceutical company, Pfizer. If the deal goes through, Taisho will receive a $22 million upfront payment. Pfizer would then gain development and marketing rights for the drug outside of Japan. Depending on the drug's progress, Taisho could then receive a number of development and milestone payments. (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.